ReviewmBio2025
The dual role of type I interferons in bacterial infections: from immune defense to pathogenesis.
Review in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Deletion of the c-di-GMP Phosphodiesterase BpdB AttenuatesInternational journal of molecular sciences · 2026Article
- Subverting Host Defense from Within: Innate Immune Modulation byPathogens (Basel, Switzerland) · 2026Review
- Review
- Germanium-embedded bioactive fabric reduces bacterial bioburden and modulates fibroblast and macrophage behaviorFrontiers in bioengineering and biotechnology · 2026Article
- The cGAS-STING pathway in pulmonary infectious and sterile inflammation: differences, connections, and therapeutic implications.Frontiers in immunology · 2026Review
- Pathogenicity and virulence ofVirulence · 2025Review
- Type I interferons in bacterial diseases: myeloid cells at the crossroads of protection and pathology.Frontiers in immunology · 2025Review
- RIG-I drives protective type I interferon production by glial cells in response toFrontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Type I interferons (IFNs) are crucial components of the human immune system, playing a key role in regulating immune activity. Existing literature has characterized their antiviral and proviral roles in viral contexts. Type I IFNs also exhibit a dual role in bacterial infections, functioning as defenders or disruptors or both based on factors including but not limited to such things as the bacterial species, infection stage, host immune status, and the route and site of infection. This review provides a summary of the signaling pathways associated with type I IFN responses and discusses the complex mechanisms of type I IFNs in bacterial infections. Because type I IFNs provide an important opportunity to develop personalized treatment strategies, which are expected to be transformed into efficient adjuvant therapy for specific infectious diseases, we also discuss the potential for targeting type I IFNs for therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.